Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
Supernus and Indivior merge to create scaled, CNS-focused entity
Through this merger, Supernus and Indivior will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs).
Read Full Article
Express Pharma
Fermenta Biotech lists equity shares on NSE
Prashant Nagre says the NSE listing strengthens Fermenta’s capital market presence and shareholder engagement The post Fermenta Biotech lists equity shares on NSE appeared first on Express Pharma.
Read Full Article
Pharma Tech
FDA grants breakthrough therapy designation to Lilly’s olomorasib
The US FDA has granted breakthrough therapy designation to Lilly olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic therapy.
Read Full Article
Express Pharma
Howden India develops Cancer Care Group Policy; AstraZeneca India adopts cover for employees
Amit Agarwal explains how Howden India developed a cancer care policy for employers, while AstraZeneca India integrates it into its employee health benefits The post Howden India develops Cancer Care Group Policy; AstraZeneca India adopts cover for employees appeared first on Express Pharma.
Read Full Article
Pharma Tech
Curium to acquire Lantheus in all-cash deal worth up to $8bn
CapVest Partners-backed Curium has agreed to acquire rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
PharmaShots
Aug 4, 2026, 1:30 PM
Key Biosimilars Events of July 2026
Shots: Company: Samsung Bioepis and Harrow Product: Byooviz Active Ingredient: Ranibizumab Reference Product: Lucentis Reference Product Company: Genentech Disease: All Approved Indications Date: Jul 01, 2026 Shots: Company: Orion Pharma and Shilpa Medicare Product: Nivolumab Active Ingredient: Nivolumab Reference Product: Opdivo Reference Product Company: BMS Disease: All Approved Indications Date: Jul 06, 2026 Shots: Company: Henlius Product: HLX05-N Active Ingredient: Cetuximab Reference Product: Erbitux Reference Product Company: Eli Lilly Disease: Metastatic Colorectal Cancer Date: Jul 08, 2026 Shots: Company: Polpharma and Teva Product: Ocrelizumab Active Ingredient: Ocrelizumab … The post Key Biosimilars Events of July 2026 appeared first on PharmaShots.
PharmaShots
Aug 4, 2026, 12:30 PM
Galaxy Therapeutics Secures CE Mark for SEAL Embolization System
Shots: Ref: PRnewswire | Image: Galaxy Therapeutics | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Galaxy Therapeutics Secures CE Mark for SEAL Embolization System appeared first on PharmaShots.
ET Pharma
Aug 4, 2026, 11:48 AM
Pathos AI to license experimental breast cancer drug from China's Jiangsu Alphamab Biopharmaceutical
Under the deal with Jiangsu Alphamab is also eligible for development and commercialization milestone payments that, together with the upfront payment, could bring the deal's total value to as much as $2.09 billion, Alphamab Oncology said in a filing to the Hong Kong stock exchange.
PharmaShots
Aug 4, 2026, 11:30 AM
Nurix Therapeutics Enrolled First Patient in P-III (DAYBreak CLL-306) Trial of Bexobrutideg in R/R CLL/SLL
Shots: Ref: Globenewswire | Image: Nurix Therapeutics | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Nurix Therapeutics Enrolled First Patient in P-III (DAYBreak CLL-306) Trial of Bexobrutideg in R/R CLL/SLL appeared first on PharmaShots.
Pharma Tech
Aug 4, 2026, 10:57 AM
Supernus and Indivior merge to create scaled, CNS-focused entity
Through this merger, Supernus and Indivior will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs).
Express Pharma
Aug 4, 2026, 10:30 AM
Fermenta Biotech lists equity shares on NSE
Prashant Nagre says the NSE listing strengthens Fermenta’s capital market presence and shareholder engagement The post Fermenta Biotech lists equity shares on NSE appeared first on Express Pharma.
News
Latest industry coverage
Google News
Aug 4, 2026, 7:33 PM
Lilly, Amplia to Evaluate Combined Investigational Treatments for Advanced NSCLC - Contract Pharma
Lilly, Amplia to Evaluate Combined Investigational Treatments for Advanced NSCLC Contract Pharma
Google News
Aug 4, 2026, 7:18 PM
Novo outlook hike falls flat as high Wegovy pill hopes unmet - Reuters
Novo outlook hike falls flat as high Wegovy pill hopes unmet Reuters
Google News
Aug 4, 2026, 7:09 PM
How to Maintain a Productive Sponsor-CMO Relationship - PharmTech.com
How to Maintain a Productive Sponsor-CMO Relationship PharmTech.com
Google News
Aug 4, 2026, 7:00 PM
Drugmakers don’t have ‘duty to innovate’, California court rules, backing Gilead in HIV drug litigation - Fierce Pharma
Drugmakers don’t have ‘duty to innovate’, California court rules, backing Gilead in HIV drug litigation Fierce Pharma
Google News
Aug 4, 2026, 6:38 PM
As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill - Fierce Pharma
As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill Fierce Pharma
Google News
Aug 4, 2026, 6:33 PM
Pathos AI Enters Two lIcensing Deals | PharmExec - Pharmaceutical Executive
Pathos AI Enters Two lIcensing Deals | PharmExec Pharmaceutical Executive
Google News
Aug 4, 2026, 6:21 PM
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts - Reuters
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts Reuters
Google News
Aug 4, 2026, 6:21 PM
Middle East chemical makers find a way around the Strait of Hormuz, and rumors of a BMS-AstraZeneca deal swirl - Chemical & Engineering News
Middle East chemical makers find a way around the Strait of Hormuz, and rumors of a BMS-AstraZeneca deal swirl Chemical & Engineering News
Google News
Aug 4, 2026, 6:20 PM
The China Debate: Biotech deserves a deeper discussion — see you in Boston - Endpoints News
The China Debate: Biotech deserves a deeper discussion — see you in Boston Endpoints News
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer